Adaptive Biotechnologies Corporation research snapshot
ADPT AI stock analysis currently reads Adaptive Biotechnologies as a commercial-stage immune medicine and diagnostics platform whose minimal residual disease (MRD) business is the clear engine: Q2 2026 revenue rose 22% year over year to $71.6 million, MRD revenue grew 33% (49% excluding milestones), gross margin climbed to 72%, and management says the company is on track for positive company-wide adjusted EBITDA and free cash flow by the end of 2026. Management also expects to identify a preferred path for separating the Immune Medicine business by year-end. This is not a certain price prediction. At the August 4, 2026 data cutoff, the reference quote used here was $22.57 (July 31, 2026 close), market capitalization was about $3.6 billion, and the stock was testing multi-year highs near $24.57. This is informational research and not investment advice.
Current price
$22.57
Market cap
About $3.6 billion
AI score
60 / 100
Rating
Improving MRD fundamentals, separation execution risk
Trend status
Strong uptrend, testing $24.57 multi-year-high resistance
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Adaptive sells a proprietary immunosequencing platform anchored by the FDA-cleared clonoSEQ MRD test. MRD produced 92% of Q2 2026 revenue, grew 33% year over year (49% excluding milestones), and generated $9.1 million of segment adjusted EBITDA. | Medium-high |
| Moat | The moat comes from the clonoSEQ FDA clearance, expanded Medicare and commercial reimbursement, proprietary sequencing chemistry, the immuneCODE data set, EMR integrations (Flatiron and a first Epic go-live), and a roughly $245 million pharma backlog. It is defensible but narrow against Natera, Guardant, and Roche. | Medium |
| Management | Management executed a decisive quarter: a $345 million zero-coupon convertible raised with capped calls and a share buyback, retirement of the OrbiMed revenue interest, a raised FY MRD outlook, and Morgan Stanley retained for the Immune Medicine separation with a preferred path expected by year-end. | Medium |
| Financial trend | Q2 2026 revenue was $71.6 million (up 22%, or 30% excluding Genentech), MRD revenue was $66.2 million, sequencing gross margin reached 72% versus 64% a year ago, and the adjusted EBITDA loss narrowed to $0.7 million from $7.2 million. GAAP net loss was $39.9 million, about $16 million excluding the one-time OrbiMed extinguishment cost. | High |
| Valuation | ADPT trades at roughly 12x trailing-twelve-month sales with no meaningful P/E because GAAP profitability is not yet reached. The premium embeds continued MRD momentum, a clean separation, and a path to breakeven. The 1-year analyst target average is about $23.90 (low $20, high $28). | Medium |
| Technical trend | ADPT is in a strong uptrend. Price holds above a rising 20-day moving average near $22, a 50-day average near $19.20, and a 100-day average near $16.50, with RSI around 57 to 60. The stock is testing the $24.18 to $24.57 resistance zone that includes the 52-week high. | Medium-high |
| Risk level | Key risks are separation execution, single-franchise concentration, competition from Natera, Guardant, and Roche, Medicare reimbursement policy, the $345 million convertible near its $24.11 conversion price, and high volatility (beta about 2.1). | Medium-high |
| AI confidence | Medium-high for the reported financials, guidance, technicals, and financing facts. Lower confidence for the Immune Medicine separation outcome and for revenue beyond 2026. | Medium-high data confidence |
| Investment certainty | Low-medium. The core MRD business is demonstrably improving and the cash runway is longer after the convertible, but the valuation already reflects optimism and the separation path is not yet decided. | Low-medium |
ADPT AI stock forecast
The ADPT AI stock forecast uses scenario ranges around the $22.57 reference price. It does not claim that AI can predict a specific future price. The bullish case requires MRD growth to hold near guidance, company-wide positive adjusted EBITDA and free cash flow by year-end 2026, and a value-accretive Immune Medicine separation. The base case assumes steady MRD growth and a slow path to GAAP profitability. The bearish case assumes separation delays, competitive pricing pressure, or dilution near the convertible conversion price.
$30 to $38
More likely if MRD clinical testing keeps growing 38% to 40%, the company reaches positive company-wide adjusted EBITDA and free cash flow by the end of 2026, gross margin keeps expanding, and the Immune Medicine separation completes on a value-accretive path without heavy dilution.
$20 to $27
More likely if MRD grows roughly in line with the raised $268 million to $278 million full-year guidance, the company nears breakeven but stays short of GAAP profitability, the separation proceeds through 2026 into 2027, and the stock stays near its current multiple of roughly 12x sales.
$12 to $17
More likely if MRD growth decelerates or competitive pricing from Natera and Guardant intensifies, the separation is delayed or disrupts operations, the convertible becomes dilutive near its $24.11 conversion price, or a broad selloff hits pre-profitability diagnostics stocks.
ADPT AI technical analysis
ADPT AI technical analysis starts from the $22.57 July 31, 2026 close, the last completed session at this data cutoff. The August 3, 2026 session traded up to about $24.57 intraday and near $23.40. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current reference price | $22.57 | The July 31, 2026 close, the last completed session at the August 4, 2026 data cutoff. The August 3, 2026 session traded up to about $24.57 intraday and near $23.40. |
| Near resistance | $24.18 to $24.57 | The July 30 post-earnings high and the 52-week high zone. A confirmed daily close above $24.57 with volume would open the next leg of the uptrend. |
| Secondary resistance | $26 to $28 | Round-number zone above the current range, near the high analyst price target. Little recent overhead supply sits between $24.57 and the mid-$20s. |
| Near support | $22.40 to $22.60 | The July 31 pullback low and the current reference close, just above the rising 20-day moving average near $22. |
| Secondary support | $21.50 to $21.70 | Mid-July swing lows. A break below this zone would signal the first meaningful loss of near-term momentum. |
| Deeper support | $19.80 to $20.90 | The July 8 and July 20 lows, with the rising 50-day moving average near $19.20 below that zone. |
| Moving averages | $22.05 / $19.21 / $16.51 | Rising 20-day, 50-day, and 100-day moving averages as of the July 31, 2026 close. Price sits above all three, consistent with an intact uptrend. |
| Momentum | RSI about 57 to 60 | Positive but not overbought at the July 31, 2026 close and during the August 3, 2026 session, a change from earlier extended readings. |
| Volume | 2.99 million shares (July 31) | The July 30 post-earnings session saw about 5.3 million shares, well above the roughly 2.7 million 20-day average. |
| Volatility | Beta 2.07 | ADPT is roughly twice as volatile as the market. Position sizing should account for large daily swings. |
| Invalidation | Close below $20.90, then $19.20 | A daily close below $20.90 would weaken near-term momentum. A break below the 50-day moving average near $19.20 would challenge the intermediate uptrend. |
ADPT AI trading strategy
The ADPT AI trading strategy is a rules-based framework, not personalized advice. It combines filing-backed business evidence, technical confirmation, position sizing, and clear invalidation levels.
Watch for a confirmed daily close above $24.18 to $24.57 with above-average volume before treating the breakout as durable. The separation catalyst (preferred path expected by year-end 2026) and the next quarterly report, expected around late October 2026, are timing factors.
A failed breakout at $24.57 or a daily close back below $21.50 should reduce confidence in the trend setup.
If ADPT pulls back toward $21.50 to $22.00 near the rising 20-day moving average without a thesis break, the risk-reward is more reasonable only if MRD growth, gross margin, cash, and the separation timeline stay intact.
Do not average down merely because the stock is down. ADPT is a volatile, pre-profitability diagnostics stock that trades at roughly 12x sales and carries separation execution risk.
Track Q3 2026 earnings (expected around late October 2026), MRD test volume and average selling price, sequencing gross margin, progress toward company-wide positive adjusted EBITDA and free cash flow, the year-end 2026 separation decision, the pharma backlog, and competitive moves from Natera and Guardant.
Lower conviction if the separation is delayed, MRD growth misses the raised guidance, gross margin stalls, or the convertible starts diluting near its $24.11 conversion price.
Investment research summary
Adaptive Biotechnologies combines proprietary immune sequencing chemistry with computational biology to detect and monitor minimal residual disease with clonoSEQ and to decode immune responses for drug discovery. The MRD diagnostics business is now the economic core, contributing 92% of Q2 2026 revenue.
The moat rests on the FDA-cleared clonoSEQ test, expanded Medicare and commercial reimbursement, blood-based testing, EMR integration (Flatiron and the first Epic go-live), and a roughly $245 million pharma backlog. It is defensible but narrow against well-capitalized competitors such as Natera, Guardant, and Roche.
The thesis can fail if the separation disrupts the MRD business or delivers little value, if Natera or Guardant take share and pricing, if Medicare limits coverage expansion, if MRD growth decelerates, or if the $345 million convertible dilutes returns near its $24.11 conversion price.
Management showed execution in Q2 2026: a $345 million zero-coupon convertible with capped calls and a share buyback, retirement of the OrbiMed revenue interest, a raised MRD outlook, and Morgan Stanley retained for the separation. Co-founder Harlan Robins is moving to a consultant role focused on the separation, which adds key-person transition risk.
MRD testing is a structurally growing field in hematologic oncology, with clonoSEQ data featured at ASCO and EHA 2026 and clinical guidelines moving MRD-guided care forward. Adoption into routine community practice is a long-term trend, though the pace and reimbursement remain variables.
At roughly 12x trailing sales with no GAAP earnings, the stock prices in continued MRD momentum, a clean separation, and a path to breakeven by the end of 2026. The margin of safety is limited if execution disappoints or the multiple compresses.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ADPT reference price | $22.57 (July 31, 2026 close) | Yahoo Finance quote snapshot | August 4, 2026 |
| Market capitalization | About $3.6 billion at the July 31, 2026 close | Yahoo Finance | August 4, 2026 |
| Q2 2026 total revenue | $71.6 million, up 22% year over year (30% excluding Genentech) | Company second quarter 2026 press release, July 29, 2026 | August 4, 2026 |
| Q2 2026 MRD revenue | $66.2 million, up 33% year over year (49% excluding milestones), 92% of total revenue | Company second quarter 2026 press release, July 29, 2026 | August 4, 2026 |
| clonoSEQ test volume | 36,111 tests in Q2 2026, up 43% year over year | Company second quarter 2026 press release and earnings call | August 4, 2026 |
| Q2 2026 net loss | $39.9 million GAAP, about $16 million excluding the one-time OrbiMed extinguishment cost | Company second quarter 2026 press release, July 29, 2026 | August 4, 2026 |
| Q2 2026 adjusted EBITDA | Loss narrowed to $0.7 million from $7.2 million a year ago | Company second quarter 2026 press release, July 29, 2026 | August 4, 2026 |
| Sequencing gross margin | 72% in Q2 2026 versus 64% a year ago | Company earnings call coverage | August 4, 2026 |
| Cash, cash equivalents and marketable securities | $371.7 million as of June 30, 2026 | Company second quarter 2026 press release, July 29, 2026 | August 4, 2026 |
| Convertible senior notes | $345 million 0% convertible notes due 2031, initial conversion price about $24.11 | Company press releases, June 17, 2026 and July 29, 2026 | August 4, 2026 |
| Full-year 2026 MRD revenue guidance | Raised to $268 million to $278 million | Company second quarter 2026 press release, July 29, 2026 | August 4, 2026 |
| TTM revenue | $308.08 million | Yahoo Finance financials | August 4, 2026 |
| TTM net income | -$63.85 million (includes the one-time OrbiMed extinguishment cost) | Yahoo Finance financials | August 4, 2026 |
| Price-to-sales ratio (TTM) | About 12.2x | Yahoo Finance | August 4, 2026 |
| EPS (TTM) | -$0.37 | Yahoo Finance | August 4, 2026 |
| 52-week price range | $10.02 to $24.57 | Yahoo Finance | August 4, 2026 |
| Beta (5Y monthly) | 2.07 | Yahoo Finance | August 4, 2026 |
This ADPT AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. ADPT is a high-volatility, pre-profitability diagnostics stock that can move sharply around earnings, separation news, reimbursement changes, and competitive announcements.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
